GLP-1 medicines and acid reflux: a symptom, a GERD diagnosis and two kinds of evidence
Heartburn and regurgitation can be symptoms of reflux. A drug label’s trial reports and a study of diagnosed GERD provide different kinds of evidence for the prescriber to review.
Reflux is reported with some GLP-1 medicines. The Wegovy injection label lists GERD in adult weight-management trials, and a separate observational study found more diagnosed GERD in people with type 2 diabetes who started a GLP-1 drug than in those who started an SGLT2 inhibitor. Neither record can diagnose the cause of an individual’s heartburn. A prescriber can review the exact product and the symptoms together.123
Put the symptom in your own words
A burning sensation behind the breastbone and food or acid coming back up are common ways people describe reflux. Nausea, fullness or a change in how food moves through the stomach are different observations. You can report both without naming the condition yourself. The gastroparesis guide explains why symptoms alone do not establish delayed stomach emptying as a diagnosis.13
Bring a short record of what you felt, whether it was present before the medicine, the exact product and any changes in other medicines. Mention symptoms that interfere with eating or swallowing. If you have signs of a heart attack, such as chest discomfort or shortness of breath, call 911. Do not assume chest symptoms are reflux because they started after a medication change.34
Compare the two records without merging their numbers
In the Wegovy label’s adult injection trial table, GERD was reported in 5% of the Wegovy group and 3% of the placebo group. That table describes adverse reactions in a specific set of trials. It is not a rate for every formulation, another drug, or someone with a different history.1
The UK cohort study instead compared adults with type 2 diabetes starting a GLP-1 receptor agonist with adults starting an SGLT2 inhibitor. The public abstract reports an estimated relative risk of 1.27 and an absolute risk difference of 0.7 per 100 people over the reported three-year estimate. The study was observational and did not randomize the choice of treatment. Its estimate for diagnosed GERD does not measure the same thing as the trial table or establish a brand-specific causal effect.2
| Describe | Why it helps |
|---|---|
| What it feels like | These terms point to different questions for evaluation. |
| What changed | It helps the clinician review the sequence without assuming causation. |
| Medicine details | Labels and adverse-event tables apply to named products and populations. |
| Swallowing or chest | These need their own assessment and should not be filed under routine heartburn. |
Find out whether the number is relative or absolute
The relative risk and absolute risk difference in the UK study describe the same comparison on different scales. A relative risk of 1.27 is not a 27-percentage-point difference. The study’s estimated absolute difference was less than one person per 100 over the reported observation window. The confidence intervals and the choice of comparison drug matter when deciding how much that result should influence a new consultation. Neither study tells you which of two drugs is responsible for a symptom in someone already taking several medications.2
Ask the clinician to distinguish a pre-existing reflux diagnosis from a new symptom after a prescription change. A report of trouble swallowing, bleeding or another symptom the NIH resource lists for evaluation should be discussed explicitly instead of being grouped under a general side-effect score.13
When comparing medical weight management programs, ask which clinician reviews new digestive symptoms and whether the program can share its medication record with your usual care team.13
Sources
- DailyMed / Wegovy prescribing information. WEGOVY (semaglutide) prescribing information. Section 6.1 reports GERD adverse reactions in specified adult injection trials; the table is not a class estimate. Accessed .
- Annals of Internal Medicine / original cohort study. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Public abstract describes the UK active-comparator new-user cohort and adjusted relative and absolute estimates. Accessed .
- National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms & Causes of GER & GERD in Adults. Distinguishes reflux symptoms and medical evaluation, including swallowing problems and gastrointestinal bleeding. Accessed .
- American Heart Association. Warning Signs of a Heart Attack. Supports calling 911 for signs of a heart attack rather than attributing chest symptoms to reflux. Accessed .